Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anteris Technologies GlobalASX:AVR -7.45%45 Debt-to-Equity is 0.01 as of Mar. 2026, which is 93% below its 10-year median of 0.14. GuruFocus rates ASX:AVR with a GF Score™ of 45/100. The stock has 5 warning signs investors should review. Among 704 Medical Devices & Instruments companies, Anteris Technologies Global ranks better than 99.86% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Anteris Technologies Global's Debt-to-Equity or its related term are showing as below:
ASX:AVR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -24.54 Med: 0.14 Max: 1.57
Current: 0.01
During the past 13 years, the highest Debt-to-Equity Ratio of Anteris Technologies Global was 1.57. The lowest was -24.54. And the median was 0.14.
ASX:AVR's Debt-to-Equity is ranked better than 99.86% of 704
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ASX:AVR: 0.01
Anteris Technologies Global (ASX:AVR) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Anteris Technologies Global Debt-to-Equity Related Terms
Anteris Technologies Global Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVR vs QDEL, INMD, CNMD: Debt-to-Equity Comparison
For the Medical Devices subindustry, Anteris Technologies Global's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global (ASX:AVR) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Anteris Technologies Global and its competitors. This is 93% below median its historical median of 0.14. According to the industry distribution chart, Anteris Technologies Global ranks #1 out of 704 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Anteris Technologies Global's Debt-to-Equity too high?
Anteris Technologies Global's current Debt-to-Equity of 0.01 is 93% below median its 10-year median of 0.14. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Anteris Technologies Global's value of 0.01 is 95.7% below this industry median. Based on the distribution chart, Anteris Technologies Global ranks #1 out of 704 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's Debt-to-Equity compare to QDEL and INMD?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #1 out of 704 companies for Debt-to-Equity. This places Anteris Technologies Global in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Anteris Technologies Global's value of 0.01 is 95.7% below this benchmark. While the company's 10-year median is 0.14 vs. the industry median of 0.23, Anteris Technologies Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anteris Technologies Global's current Debt-to-Equity of 0.01 is 95.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current Debt-to-Equity is 0.01, which is 93% below median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current Debt-to-Equity of 0.01. The current Debt-to-Equity is 0.01, which is 93% below median its 10-year median of 0.14 and 95.7% below the Medical Devices & Instruments industry median of 0.23. Anteris Technologies Global's overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
45GF Score
Get the complete analysis for ASX:AVR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
